Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More

Geron Corp (GERN)

Geron Corp (GERN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Geron Appoints Vice President, Human Resources

Geron Corporation (Nasdaq: GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the...

GERN : 1.46 (-3.95%)
Geron Stock Up More Than 50% in 2019 So Far: Here's Why

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

CELG : 93.19 (-0.30%)
JNJ : 144.24 (+0.82%)
XLRN : 39.60 (-1.35%)
GERN : 1.46 (-3.95%)
Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress

Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company's first-in-class telomerase inhibitor, have been accepted for...

GERN : 1.46 (-3.95%)
Geron Provides Imetelstat Program Update

Geron Corporation (Nasdaq: GERN) today provided an update to its 2019 corporate objectives for the imetelstat program.

GERN : 1.46 (-3.95%)
Geron Continues to Build Senior Leadership of Its Development Team

Geron Corporation (Nasdaq: GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing....

GERN : 1.46 (-3.95%)
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up

Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.

JNJ : 144.24 (+0.82%)
ALDR : 11.04 (-1.43%)
EDIT : 22.83 (+4.77%)
GERN : 1.46 (-3.95%)
Geron: 1Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Thursday reported a loss of $10.1 million in its first quarter.

GERN : 1.46 (-3.95%)
Geron Corporation Reports First Quarter 2019 Financial Results

Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2019. As of the quarter-end, the Company had approximately $170 million in cash and marketable securities,...

GERN : 1.46 (-3.95%)
Geron Expands Senior Leadership of Its Development Team

Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team's senior leadership with the addition of three highly experienced professionals for key functional areas. Their oncology...

GERN : 1.46 (-3.95%)
Healthcare Companies Search for New Ways to Oppose the Spread of Cancer

Cancer is among one of the leading causes of death in the world since many countries are burdened by the lack of access to adequate healthcare, which results in the high number of deaths. In 2018, the...

CRIS : 1.70 (+4.29%)
CVM : 7.19 (-17.07%)
GERN : 1.46 (-3.95%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
NLNK : 1.56 (+1.30%)
Why International Regulations on Clinical Trials can Actually Reduce Costs and Shorten Time to Market

Every business or industry strives to improve quality, reduce costs and improve their products time to market. This, surprisingly, is true for the biotechnology industry as well. Usually regulations increase...

TEVA : 8.81 (+6.79%)
OPK : 2.00 (-1.48%)
GERN : 1.46 (-3.95%)
GILD : 68.48 (-0.52%)
MBRX : 1.20 (-0.83%)
Latest Biotechnology Advancements may be Key to Unlock new Autism Treatments

According to the Centers for Disease Control, autism affects an estimated 1 in 59 children in the United States today. The Autism Speaks website defines the main problem for researchers/practitioners...

QBIO : 1.5300 (+3.38%)
GERN : 1.46 (-3.95%)
INSM : 25.59 (-1.77%)
PHAS : 12.42 (+6.43%)
CMRX : 3.36 (-1.18%)
Why Is Geron (GERN) Up 27.3% Since Last Earnings Report?

Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GERN : 1.46 (-3.95%)
New Research: Key Drivers of Growth for Geron, Hess, Royal Gold, Lear, Menlo Therapeutics, and CorEnergy Infrastructure Trust -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Geron Corporation (NASDAQ:GERN),...

MNLO : 6.02 (-1.31%)
CORR : 39.54 (-1.42%)
HES : 62.19 (+0.97%)
LEA : 138.04 (-0.04%)
GERN : 1.46 (-3.95%)
RGLD : 101.26 (+0.23%)
Geron to Present at Needham Healthcare Conference

Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 18th Annual Needham Healthcare Conference...

GERN : 1.46 (-3.95%)
Geron Appoints Two New Independent Board Members

Geron Corporation (Nasdaq: GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O'Farrell as independent members of its Board of Directors. In addition, Ms. Bir will serve as a member...

GERN : 1.46 (-3.95%)
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 78,400 shares of Geron common stock as inducements to two newly-hired employees...

GERN : 1.46 (-3.95%)
Do Options Traders Know Something About Geron (GERN) Stock We Don't?

Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.

GERN : 1.46 (-3.95%)
Advancing Clinical Trials for Leukemia Patients is Helping Improve Survival Rate

According to the Leukemia & Lymphoma Society, the world's largest voluntary health agency dedicated to blood cancer, In 2018, 60,300 people are expected to be diagnosed with leukemia and that there are...

AKTX : 2.08 (-0.48%)
CELG : 93.19 (-0.30%)
LLY : 115.36 (-0.23%)
GERN : 1.46 (-3.95%)
CELGZ : 0.70 (+9.48%)
MBRX : 1.20 (-0.83%)
Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up

Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.

CELG : 93.19 (-0.30%)
GHDX : 54.06 (+1.03%)
JNJ : 144.24 (+0.82%)
GERN : 1.46 (-3.95%)

Van Meerten Stock Picks

ANI Pharmaceutials
My Pick of the Day belongs to the biomedical company ANI Pharmaceuticals(ANIP).
ANIP +1.05
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar